Healthy adults
Conditions
Interventions
The new skincare formulation (FQWO71W1) and placebo will be applied repeatedly to areas of rough skin
Sponsors
FANCL Corporation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Men and women aged 20 to 60 years at the time of informed consent. 2)Able to visit the testing site and undergo the required examinations on the designated dates. 3)Deemed eligible for participation in this study by the principal investigator.
Exclusion criteria
Exclusion criteria: 1)Individuals with severe atopic dermatitis. 2)Individuals receiving hormone replacement therapy. 3)Individuals with a history of allergy to cosmetics or drugs, or those with sensitive skin. 4)Individuals who are pregnant, possibly pregnant, or breastfeeding. 5)Individuals with or suspected of having severe cardiac, renal, or hepatic impairment, or circulatory diseases. 6)Individuals who are currently undergoing or have undergone within the past 3 months treatments that may affect skin function, such as chemical peels, laser treatments, or the use of physician-prescribed medications including hydroquinone, high-concentration vitamin C, and retinoic acid on the forearm. 7)Individuals currently participating in other clinical trials. 8)Individuals with large scars, warts, or rashes on the medial aspect of the forearm. 9)Individuals deemed ineligible by the study investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Observation of skin condition after repeated use of a new skincare formulation (FQWO71W1) | — |
Countries
Japan
Contacts
Public ContactYoko Imai
FANCL Corporation Research Institute
Outcome results
None listed